Recent Company News

• 09:29 PM ET Jul 02, 2026
  

  StreetAccount Sector Summary - China Healthcare June Recap

• 07:51 AM ET Jul 02, 2026
  

  CSPC Pharmaceutical Group obtains NMPA clinical trial approval for recombinant herpes zoster vaccine SYS6052 (HK$7.55, 0.00)

• 06:58 AM ET Jul 02, 2026
  

  CSPC Pharmaceutical Group starts phase I trial of SYH2095 for advanced malignant tumours in China (HK$7.55, 0.00)

• 05:06 AM ET Jul 02, 2026
  

  CSPC Innovation Pharma receives NMPA's breakthrough therapy designation for SYS6043 (CNY 34.49, 0.00)

• 04:37 AM ET Jul 02, 2026
  

  CSPC Pharmaceutical Group enters collaboration and licensing agreement with AstraZeneca for siRNA drugs (HK$7.55, 0.00)

• 10:10 AM ET Jun 30, 2026
  

  CSPC Pharmaceutical Group initiates phase III clinical trial of SYS 6010 combined with Enlonstobart (HK$6.97, 0.00)

• 11:39 AM ET Jun 29, 2026
  

  China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list

• 11:05 PM ET Jun 28, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 06:03 AM ET Jun 26, 2026
  

  CSPC Pharmaceutical initiates phase III China study of SYS6010 combined with enlonstobart for driver-gene negative non-small cell lung cancer (HK$6.69, 0.00)

• 05:57 AM ET Jun 26, 2026
  

  China's NMPA to grant breakthrough therapy designation to CSPC Pharmaceutical Group's SYS6043 in platinum-resistant ovarian cancer, primary peritoneal cancer and fallopian tube cancer (HK$6.69, 0.00)